<DOC>
	<DOC>NCT00694863</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.</brief_summary>
	<brief_title>Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<mesh_term>Adrenocorticotropin zinc</mesh_term>
	<mesh_term>Cosyntropin</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Biopsyproven idiopathic membranous nephropathy. Nephrotic syndrome: proteinuria &gt; 3.5 g/day and serum albumine &lt; 30 g/l Normal or mildly impaired renal function (eGFR &gt; 60 ml/min, MDRD formula) High risk for renal failure: beta2microglobulin excretion &gt; 500 ng/min Relative contraindication for cyclophosphamide treatment: fertility and wish for (future) family expanding high age ( &gt; 60 years) former cyclophosphamide treatment intolerance to cyclophosphamide Clinical,biochemical or histological signs of any underlying systemic disease Any infectious disease (including latent tuberculosis and/or latent amoebiasis) Active gastric or duodenal ulcers Pregnancy, lactation, inadequate contraceptives Clinical signs of renal vein thrombosis Asthma and /or any allergic conditions or hypersensitivity reactions Allergic reaction to synthetic ACTH in the past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>high risk for ESRD</keyword>
	<keyword>immunosuppressive treatment</keyword>
	<keyword>membranous nephropathy</keyword>
	<keyword>ACTH</keyword>
</DOC>